Triclabendazole, sold under the brand name Egaten among others, is a medication used to treat fascioliasis and paragonimiasis. It is very effective for both conditions. Treatment in hospital may be required. It is taken by mouth with typically one or two doses being required
Anant Labs manufacture and furnish high quality Triclabendazole impurities for global markets. Our Triclabendazole EP Impurities are used by API manufacturers and fully integrated pharmaceutical companies worldwide.
Synonyms
6-chloro-5-(2,3-dichlorophenoxy)-2-methylsulfanyl-1H-benzimidazoleTriclabendazole68786-66-3FasinexTriclabendazolEgatenTriclabendazolum5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazoleNVP-EGA230EGA230BDTXSID70439521H-Benzimidazole, 6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-NSC-7592504784C8E03ODTXCID50239526-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-1,3-benzodiazoleEgaten tm6-chloro-5-(2,3-dichlorophenoxy)-2-methylthiobenzimidazoleRefChem:58513Triclabendazole MicronizedP02BX04614-728-76-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazoleMFCD00864519CPD000466357MLS001424101CHEMBL10864405-Chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazoleNCGC00164610-01SMR0004663575-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLSULFANYL)-1H-1,3-BENZODIAZOLEC14H9Cl3N2OS5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzo[d]imidazole6-chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)-1H-benzimidazole6-[2,3-bis(chloranyl)phenoxy]-5-chloranyl-2-methylsulfanyl-1H-benzimidazoleTriclabendazol [INN-Spanish]Triclabendazolum [INN-Latin]CCRIS 89886-Chloro-5-(2,3-dichlorophenoxy)-2-methylthio-benzimidazoleCGA 89317UNII-4784C8E03OTriclabendazole CRSFasinex (TN)CGA-89317Egaten (TN)Triclabendazole (Standard)Triclabendazole 100 microg/mL in Acetonitrile1H-BENZIMIDAZOLE, 5-CHLORO-6-(2,3-DICHLOROPHENOXY)-2-(METHYLTHIO)-CGA-89317, EgatenTRICLABENDAZOLE [MI]Oprea1_236106Triclabendazole (USAN/INN)TRICLABENDAZOLE [INN]cid_50248MLS000759473MLS000876812SCHEMBL165712TRICLABENDAZOLE [USAN]orb1310247orb3024998SCHEMBL3499260TRICLABENDAZOLE [MART.]SCHEMBL29394758SCHEMBL29409229TRICLABENDAZOLE [WHO-DD]BDBM58491CHEBI:94759HY-B0621RMSK5581Triclabendazole [USAN:INN:BAN]5-Chloro-6-(2,3-dichlorophenoxy)-2-methylthiobenzimidazoleHMS2051E16HMS2232D14HMS3370H02HMS3393E16HMS3652M16HMS3715P16HMS3744I09HMS5082G16KUC103451NPharmakon1600-01505786CGA89317HY-B0621Tox21_112231EBC-26788EBC-84235MSK5581-100AMSK5581-100MNSC759250s4114STK332284TRICLABENDAZOLE [ORANGE BOOK]AKOS005439340AKOS015950804MSK5581-1000MAC-7627AT10531CCG-100881CCG-268150DB12245FT28419KS-5329NC00131NSC 759250SB17173NCGC00164610-02NCGC00164610-08SBI-0207022.P001Triclabendazole for system suitability CRSCAS-68786-66-3NS00000576SW197511-2Triclabendazole 100 |Ig/mL in AcetonitrileD07364Triclabendazole Solution in Methanol, 100ug/mLAB00639964-10AB00639964_12AB00639964_13Triclabendazole Solution in Methanol, 1000ug/mLF079305Q419739SR-01000759363SR-01000759363-4Triclabendazole Solution in Acetonitrile, 100ug/mLTriclabendazole, VETRANAL(TM), analytical standardBRD-K81916719-001-05-5BRD-K81916719-001-13-9BRD-K81916719-001-14-7Z30692810926-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazoleTriclabendazole, EuropePharmacopoeia (EP) Reference Standard5-Chloro-6-(2',3'-dichlorophenoxy)-2-(methylthio)benzimidazole6-Chloro-5-(2,3-dichlorophenoxy)-2-(methylthio) -1H-benzimidazole5-Chloro-6-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-1,3-benzimidazole6-chloro-5-(2,3-dichlorophenoxy)-2-(methylsulfanyl)-1H-benzimidazole5-[2,3-bis(chloranyl)phenoxy]-6-chloranyl-2-methylsulfanyl-1H-benzimidazole6-CHLORO-2-(METHYLSULFANYL)-1H-1,3-BENZIMIDAZOL-5-YL (2,3-DICHLOROPHENYL) ETHERTriclabendazole for system suitability, EuropePharmacopoeia (EP) Reference StandardJA9
